NSE · VALIANTLAB
Valiant Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹73 Cr with net profit ₹9 Cr — a 12.91% net margin, versus -1.36% the period before.
Shareholding
As of 2026-09-30
- Promoter74.94%
- Public24.91%
- FII0.07%
- DII0.08%
14,618 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.86× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 2. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #56 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,15,997 Cr | 32.92 | 4.98 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,14,942 Cr | 23.54 | 4.24 | 18.59% | 16.09% |
| Laurus Labs Limited | ₹1,10,796 Cr | 101.31 | 20.9 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹1,09,735 Cr | 34.06 | 2.88 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,08,699 Cr | 30.37 | 3.16 | 11.27% | 12.06% |
| Mankind Pharma Limited | ₹94,108 Cr | 44.11 | 5.77 | 11.74% | 13.86% |
| Aurobindo Pharma Ltd. | ₹91,416 Cr | 24.18 | 2.41 | 9.25% | 10.7% |
| Lupin Limited | ₹88,696 Cr | 14.89 | 3.95 | 23.76% | 18.72% |
| Glenmark Pharmaceuticals Ltd. | ₹62,789 Cr | 20.12 | 5.97 | 28.08% | 10.22% |
| Alkem Laboratories Ltd. | ₹59,669 Cr | 26.19 | 4.32 | 16.66% | 14.31% |
| Valiant Laboratories Ltd.(this company) | ₹684 Cr | 42.67 | 2.2 | -1.05% | 5.23% |
AI analysis
AI-generated · google/gemini-2.5-flashValiant Laboratories Ltd. is listed with a market capitalization of Rs 348 Cr. The company reported revenue of Rs 138.82 Cr with a revenue growth of -26.7%. Its profit margin is -138.1% and debt-to-equity ratio is 0.42. As of June 30, 2026, promoter holding stands at 74.9394% and public holding at 25.0606%.
Positives
- +The debt-to-equity ratio is 0.42 which is relatively low.
- +Promoter holding of 74.9394% as of June 30, 2026 indicates significant control.
- +No promoter pledge was reported.
Negatives
- −Revenue declined by -26.7% to Rs 138.82 Cr.
- −The company recorded a negative profit margin of -138.1%.
- −Return on equity (ROE) is significantly negative at -105.1%.
- −Earnings per share (EPS) is negative at Rs 0.
- −The trailing twelve months PE ratio is 198.25, which is elevated.
Financial Performance
In the Mar 2025 financial year, Valiant Laboratories Ltd. reported a revenue of Rs 138.82 Cr, marking a -26.7% decline from the previous period. The company recorded a net loss of Rs -2.2012 Cr, resulting in an EPS of -0.51. The EBITDA for the Mar 2025 period was -1.3373.
Profitability & Returns
The company's profitability saw a profit margin of -138.1%. Return on equity (ROE) for Valiant Laboratories Ltd. was -105.1%, while return on capital employed (ROCE) stood at 0.7384%.
Balance Sheet
Valiant Laboratories Ltd. has a book value of Rs 57.24. The debt-to-equity ratio is 0.42, indicating its leverage position. No dividend yield was reported for the company.
Ownership & Pledges
As of June 30, 2026, the promoter holding in Valiant Laboratories Ltd. was 74.9394%, with public holding at 25.0606%. There was no reported pledge of promoter shares. The number of shareholders as of this period was 14341.
Data as of — price: 2026-10-26 · financials: Jun 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.